Circassia

Circassia is a specialty biopharmaceutical company focused on developing world-class immunotherapies. These include a new class of T-cell vaccines designed to treat a broad range of allergies, and therapies to combat autoimmune conditions such as rheumatoid arthritis and psoriasis. The Company has made rapid progress since its establishment in 2006, and several of its products are currently in mid- to late-stage development, having successfully completed a number of phase II clinical studies.
Type: NORMAL
Address: Magdalen Centre The Oxford Science Park Oxford OX4 4GA
Website: http://www.circassia.co.uk
Phone: +44 (0)1865 784574
Fax: +44 (0)1865 784576
Email: Charlesswingland@circassia.co.uk
 
This website requires Flash Player 9 or later. If you can not view this site you probably need to update your system with this plug-in for your browser.